Evidence map›Paper›PMID 36207777›Full record

ArticleThe Prostate2023

Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.

Wei Ou, Jiahao Lei, Minghao Li, Xinyao Zhang, Ruiming Liang, Lingli Long, Changxuan Wang, Lingwu Chen, Junxing Chen, Junlong Zhang and 1 more

Abstract read
In one paragraph

Article in The Prostate, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei OuDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jiahao LeiDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-1840-3022
Minghao LiDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xinyao ZhangDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ruiming LiangClinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Lingli LongClinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Changxuan WangDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Lingwu ChenDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Junxing ChenDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Junlong ZhangDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zongren WangDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

National Natural Science Foundation of China 81901849
6 · The paper itself

Abstract

backgroundPatients undergoing prostate biopsies (PBs) suffer from low positive rates and potential risk for complications. This study aimed to develop and validate an ultrasound (US)-based radiomics score for pre-biopsy prediction of prostate cancer (PCa) and subsequently reduce unnecessary PBs.

methodsBetween December 2015 and March 2018, 196 patients undergoing initial transrectal ultrasound (TRUS)-guided PBs were retrospectively enrolled and randomly assigned to the training or validation cohort at a ratio of 7:3. A total of 1044 radiomics features were extracted from grayscale US images of each prostate nodule. After feature selection through the least absolute shrinkage and selection operator (LASSO) regression model, the radiomics score was developed from the training cohort. The prediction nomograms were developed using multivariate logistic regression analysis based on the radiomics score and clinical risk factors. The performance of the nomograms was assessed and compared in terms of discrimination, calibration, and clinical usefulness.

resultsThe radiomics score consisted of five selected features. Multivariate logistic regression analysis demonstrated that the radiomics score, age, total prostate-specific antigen (tPSA), and prostate volume were independent factors for prediction of PCa (all p < 0.05). The integrated nomogram incorporating the radiomics score and three clinical risk factors reached an area under the curve (AUC) of 0.835 (95% confidence interval [CI], 0.729-0.941), thereby outperforming the clinical nomogram which based on only clinical factors and yielded an AUC of 0.752 (95% CI, 0.618-0.886) (p = 0.04). Both nomograms showed good calibration. Decision curve analysis indicated that using the integrated nomogram would add more benefit than using the clinical nomogram.

conclusionThe radiomics score was an independent factor for pre-biopsy prediction of PCa. Addition of the radiomics score to the clinical nomogram shows incremental prognostic value and may help clinicians make precise decisions to reduce unnecessary PBs.

Indexed as

Prostatic NeoplasmsHumansMaleRetrospective Studiesnomogramprostate cancerradiomicsultrasound

Identifiers

PMID36207777
PMCPMC10092021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.